IRLAB is granted additional patent for drug candidate mesdopetam
IRLAB is granted additional patent for drug candidate mesdopetam that expands its patent protection
Gothenburg, Sweden, September 4, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project.
“The already strong patent protection for mesdopetam is now expanded with a patent, EP3976581B1, which protects the active pharmaceutical ingredient of mesdopetam used in clinical development. With the extended protection, there is potential to extend market exclusivity for mesdopetam right up to the early 2040s, which is incredibly positive for the value of mesdopetam,” said Kristina Torfgård, CEO of IRLAB.
Mesdopetam has a vast clinical potential for unmet medical needs in Parkinson’s disease. The drug candidate is intended to treat people with Parkinson’s who develop levodopa induced dyskinesias (PD-LIDs), which is more than 30 percent of all people living with Parkinson’s. This equates to more than 1.5 million affected individuals in the eight major markets worldwide.
Mesdopetam has previously been granted a family of substance patents in all major markets worldwide. The newly approved patent covers a salt of mesdopetam which is used in the formulations in the ongoing clinical development. The patent expires in 2040. With the potential grant of a supplementary protection certificate (SPC) exclusivity can reach into the early 2040s.
Latest Posts
- Mobile Internet Services Disrupted in Doda, Authorities yet to Bring Clarity
July 17, 2026 | Breaking News, Doda, Jammu Kashmir - One killed, three SOG personnel injured in firing incident in Bhaderwah, Jammu Kashmir
July 17, 2026 | Breaking News, Jammu Kashmir, Kishtwar - Strait of Hormuz Is a Red Line: Iran
July 16, 2026 | Breaking News, World - Kerala High Court Pauses Waqf Board Functioning Over Composition Row
July 16, 2026 | Breaking News, Courts & Law, India - Probe Agency Directorate of Enforcement (ED) Raids 13 Locations In UP Over Rohingya Terror Funding Network
July 16, 2026 | Breaking News, India, Politics - ISRO Tightens Rules on Scientist Resignations; More than 100 resigned in recent months
July 16, 2026 | Breaking News, India, Science & Technology - Trinamool Congress Faces Setback; Rajya Sabha MP Koel Mallick Resigns
July 16, 2026 | Breaking News, India, Politics - Activist Sonam Wangchuk Refuses to End Fast, Urges Public to Join July 20 Protest
July 16, 2026 | Breaking News, India, Politics - Delhi Cabinet Approves Delhi Right of Citizen to Time-Bound and Ease of Delivery of Service Bill, 2026, Penalties for Delays
July 15, 2026 | Breaking News, India, Politics - India Must Listen Before a Life Is Lost; Urgent Letter of Hindus for Human Rights
July 15, 2026 | Press Release